SARTORIUS (SARTF)
(Delayed Data from OTC)
$207.46 USD
0.00 (0.00%)
Updated Sep 5, 2024 03:59 PM ET
5-Strong Sell of 5 5
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
SARTORIUS [SARTF]
Reports for Purchase
Showing records 1 - 20 ( 28 total )
Company: SARTORIUS
Industry: Medical - Instruments
Company: SARTORIUS
Industry: Medical - Instruments
Rating Upgrade to Overweight as Bioproduction Moves Past Destocking
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Company: SARTORIUS
Industry: Medical - Instruments
3Q23 - Biotech Revolution Resumes; Destocking Subsides with AVTR, DHR, RGEN Next
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
SATG Preannouncement Suggests BioProcess Bottoming, Lab Equipment Lag
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
GLP-1 Market Update: Potential Exceeding Past Estimates, Injection vs. Oral Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Company: SARTORIUS
Industry: Medical - Instruments
Sartorius Update: Lowered Revenue Guidance and Implications for AVTR, DHR, RGEN, TMO
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
1Q23 - Reiterating FY23 Outlook Despite 1Q Miss
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
1Q23 Results Miss; Reset More in Line with DHR and RGEN Estimates
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Sartorius 4Q Orders Shift Industry Tone for 2023
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Bookings Drop as COVID Recedes - DHR, TMO, RGEN, AVTR Implications
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
3Q22 - Transitory COVID Risk; DHR, TMO, RGEN, AVTR
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Albumedix Acquisition - Bioprocess Media Market
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Strong Start to Life Science Earnings Season
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Much More to Bioprocess Demand Than COVID
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Bioproccessing Growth into 2022-2025 Overwhelming Covid Puts and Takes
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Life Science Tools: A Pivotal Upcoming Week Providing Key 2022 Read-Throughs for the Sector
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: SARTORIUS
Industry: Medical - Instruments
Earnings Season Launched with Large Beat - DHR, TMO, RGEN, WST, MRVI
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department